[Form 3] Prelude Therapeutics Inc Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Prelude Therapeutics (PRLD) reported an insider filing: a Form 3 initial statement of beneficial ownership tied to an event on 10/17/2025.

The filing identifies the reporting person as a Director and states in the remarks that no securities are beneficially owned. It was filed by one reporting person and signed by /s/ Bryant D. Lim, Attorney-in-Fact pursuant to an Exhibit 24 Power of Attorney. This sets the insider’s baseline ownership as of the reported date.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dorton Katina

(Last) (First) (Middle)

C/O PRELUDE THERAPEUTICS INCORPORATED

175 INNOVATION BOULEVARD

(Street)

WILMINGTON DE 19805

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/17/2025

3. Issuer Name and Ticker or Trading Symbol
Prelude Therapeutics Inc [ PRLD ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Bryant D. Lim, Attorney-in-Fact	10/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did PRLD file?

A Form 3, the initial statement of beneficial ownership by an insider.

What is the insider’s relationship to Prelude Therapeutics (PRLD)?

The reporting person is a Director.

How many PRLD securities are beneficially owned according to the filing?

The remarks state No securities are beneficially owned.

What is the event date triggering the Form 3?

The event date is 10/17/2025.

Who signed the Form 3 for PRLD?

It was signed by /s/ Bryant D. Lim, Attorney-in-Fact.

Was the Form 3 filed by multiple reporting persons?

No. It was filed by one reporting person.

Does the filing reference a Power of Attorney?

Yes. Remarks note Exhibit 24 - Power of Attorney.